---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-385430"
form_type: "8-K"
ticker: "EVMN"
cik: "0002044725"
company_name: "Evommune, Inc."
filed_at: "2026-09-08T22:05:32+00:00"
generated_at: "2026-09-09T10:05:31.981522+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Evommune's EVO756 Phase 2b fails in atopic dermatitis; AD program halted

## Summary
- Phase 2b trial of EVO756 in 121 adults with moderate-to-severe AD missed primary and secondary endpoints at all doses.
- Company will cease EVO756 development for AD; will continue evaluation in migraine prophylaxis.
- EVO301 (IL-18BP fusion protein) becomes lead AD program; Phase 2b planned for mid-2027 after positive Phase 2a data.
- Cash, equivalents, and investments expected to fund operations into 2029.

## SEC filing metadata
- accession: 0001193125-26-385430
- form_type: 8-K
- ticker: EVMN
- cik: 0002044725
- company_name: Evommune, Inc.
- filed_at: 2026-09-08T22:05:32+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2044725/000119312526385430/0001193125-26-385430-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2044725/000119312526385430/evmn-20260908.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-385430
- JSON: https://secwatch.observer/filing/0001193125-26-385430.json
- Plain text: https://secwatch.observer/filing/0001193125-26-385430.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.